A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Co

Project: Research project

Description

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
StatusActive
Effective start/end date4/30/166/30/20

Funding

  • MIRATI THERAPEUTICS, INC.

Fingerprint

Histone Deacetylase Inhibitors
Non-Small Cell Lung Carcinoma
Neoplasms
mocetinostat